M

Monopar Therapeutics
D

MNPR

41.480
USD
1.48
(3.70%)
مغلق
حجم التداول
1,664
الربح لكل سهم
-3
العائد الربحي
-
P/E
-21
حجم السوق
253,132,861
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
الأخبار
المقالات

العنوان: Monopar Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidiveforthe prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.